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ABSTRACT
Chronic kidney disease (CKD) expands the prior concept of chronic renal insufficiency by including patients with relatively
preserved renal function, as assessed by the estimated glomerular filtration rate (eGFR), as even these early CKD stages are
associated with an increased risk for all-cause death and cardiovascular death, CKD progression and acute kidney injury.
A decreased eGFR (<60 mL/min/1.73 m2) is by itself diagnostic of CKD when persisting for >3 months. However, when eGFR
is 60 mL/min/1.73 m2, an additional criterion is required to diagnose CKD. In a recent clinical trial published in The New
England Journal of Medicine, all 6190 participants were reported to have CKD: 47% had Stages 1 and 2 CKD and 53% had Stage 3
CKD. This illustrates a widespread misunderstanding of the concept of CKD. Moreover, CKD categories in this study were
assigned based on the estimated creatinine clearance. Since both estimated creatinine clearance and creatinine clearance
overestimate eGFR, this illustrates another frequent misunderstanding: equating GFR with creatinine clearance. In this
commentary, we clarify the concept of CKD and of CKD categories for non-nephrologists. Assigning a diagnosis of CKD to a
patient with normal renal function and absence of other evidence of CKD may have negative consequences for the
individual (e.g. insurance and others) as well as for the medical community at large by creating confusion about the
concept.
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WHAT IS CHRONIC KIDNEY DISEASE?
The current international consensus definition of chronic kid-
ney disease (CKD) by Kidney Disease: Improving Global
Outcomes (KDIGO 2012) states that CKD is defined as
abnormalities of kidney structure or function, present for
> 3 months, with implications for health [1]. The abnormalities
of kidney structure or function may be recognized clinically by
different criteria: just one of these criteria is enough to diagnose
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CKD. Criteria include a decreased glomerular filtration rate
(GFR) [<60 mL/min/1.73 m2) or evidence of kidney damage such
as albuminuria (albumin excretion rate  30 mg/24 h; urinary al-
bumin creatinine ratio (UACR)  30 mg/g], urine sediment ab-
normalities, electrolyte and other abnormalities due to tubular
disorders, abnormalities detected by histology, structural abnor-
malities detected by imaging or history of kidney transplanta-
tion. In clinical practice, this means that in order to diagnose
CKD in an individual with normal GFR or with GFR 60 mL/min/
1.73 m2, a urine analysis or kidney imaging test is required.
WHAT ARE THE IMPLICATIONS FOR HEALTH
OF CKD MENTIONED IN THE KDIGO
DEFINITION?
A diagnosis of CKD is associated with an increased risk of CKD
progression, all-cause death, cardiovascular death and acute
kidney injury, among others [1]. These risks have been demon-
strated most clearly for pathological albuminuria or decreased
GFR [2–4].
HOW IS CKD CATEGORIZED?
CKD categories are recognized based on GFR (G categories G1
through G5) and on albuminuria (A categories A1 through A3).
Increasing CKD categories are associated with increasing risks
of CKD progression, all-cause death, cardiovascular death and
acute kidney injury. G1 (GFR 90 mL/min/1.73 m2) and A1
(UACR<30 mg/g) categories represent normal values and, thus,
are not diagnostic by themselves of CKD. Patients in category
G1A1 are required to fulfill an additional criterion for CKD in
order for the physician to diagnose CKD. If this additional crite-
rion were not required to diagnose CKD, then the whole general
population would be considered to have CKD, resulting in a CKD
prevalence of 100%!
KDIGO recommends that CKD is classified based on cause
(C), GFR category (G) and albuminuria (A) category, that is, it rec-
ommends using a CGA classification [1]. A heatmap represent-
ing risk of CKD progression according to GFR and albuminuria
categories has become very popular (Figure 1). Its popularity
may be the driving force for two oversimplifications that we
have observed in non-nephrologists during routine clinical
practice: (i) assuming that CKD followed by a G category and an
A category (e.g. CKD G3A2) is in itself a diagnosis, thus forgetting
about the key issue of cause, and (ii) assuming that all combina-
tions of categories in the image are, by themselves, diagnostic
of CKD, that is, using the term CKD to refer to a patient with
G1A1, G1A2, G2A1 or G2A2 categories in the absence of other ev-
idence of CKD, as can be observed in Table 1 from a recent The
New England Journal of Medicine (NEJM) clinical trial report [5].
CAN CKD BE DIAGNOSED IN INDIVIDUALS
WITH NORMAL GFR?
Yes indeed. CKD can be diagnosed when GFR is normal (i.e.
90 mL/min/1.73 m2) if there is other evidence of kidney dam-
age such as albuminuria (albumin excretion rate 30 mg/24 h;
UACR 30 mg/g), urine sediment abnormalities, electrolyte and
other abnormalities due to tubular disorders, abnormalities
detected by histology, structural abnormalities detected by im-
aging or history of kidney transplantation. However, if GFR is
FIGURE 1: Heatmap representing the risk for CKD progression according to GFR and albuminuria categories [1]. Similar heatmaps represent the risk for all-cause death
and cardiovascular death.
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normal, then CKD cannot be diagnosed in the absence of at least
one positive study exploring these items.
CAN CKD BE DIAGNOSED IN INDIVIDUALS
WITH NORMAL GFR AND NORMAL
ALBUMINURIA?
Yes indeed. CKD can be diagnosed when GFR is normal (i.e.
90 mL/min/1.73 m2) and albuminuria is normal (<30 mg/g) if
there is other evidence of kidney damage persisting longer than
3 months, such as urine sediment abnormalities, electrolyte
and other abnormalities due to tubular disorders, abnormalities
detected by histology, structural abnormalities detected by im-
aging or history of kidney transplantation. However, when both
GFR and albuminuria are normal, CKD cannot be diagnosed in
the absence of at least one positive study exploring these items.
As an example, an individual with autosomal dominant poly-
cystic kidney disease having the kidney replaced by numerous
large cysts that increase the kidney size may be diagnosed with
CKD despite normal GFR and albuminuria. This patient will
have CKD G1A1 caused by polycystic kidney disease. In another
example, it may be argued that all classical Fabry males be con-
sidered to have CKD G1A1 caused by Fabry disease when GFR
and albuminuria values are normal, since the disease is known
to be characterized by glycolipid deposits in podocytes and en-
dothelial and other kidney cells that are already evident in
childhood, that is, it is known to be associated with histological
evidence of CKD [6].
HOW SHOULD GFR BE ASSESSED?
KDIGO recommends using serum creatinine and a GFR estimat-
ing equation for initial assessment of GFR. It additionally rec-
ommends that clinicians understand clinical settings in which
estimated GFR (eGFR) creatinine is less accurate (e.g. muscle
mass, that is creatinine generation, much lower or much higher
than expected for age and sex). In this regard, for the review of
evidence on GFR estimating equations, KDIGO only considered
equations that were developed using assays that were traceable
to reference methods and study populations in which serum
creatinine concentration was measured using traceable assays,
that is, the Modification of Diet in Renal Disease (MDRD) Study
equation, Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation and modifications of these. The Cockcroft
and Gault formula is explicitly indicated not to be based on
traceable assays. Furthermore, Cockcroft and Gault estimates
creatinine clearance, which usually overestimates eGFR [7].
Thus, the use of the Cockcroft and Gault formula may result in
assigning individual patients to different G categories than us-
ing the CKD-EPI or MDRD equations, as discussed extensively in
reference [7]. Measuring GFR is more accurate, and iohexol-
based methods allow clinical GFR measurement in patients for
whom a precise assessment of GFR is clinically relevant or in
whom creatinine-based equations are not reliable [8, 9].
WHAT ARE THE ISSUESWITH THE RECENT
NEJM PUBLICATION?
A recent 2018 publication in NEJM reported the results of a ran-
domized clinical trial comparing the safety of allopurinol and
febuxostat treatment to decrease serum urate levels [5, 10].
Table 1 in this manuscript describes the baseline characteristics
of the participants (Figure 2). Apparently, 100% of the 6190
patients had CKD since they are represented as either having
Stage 1 or 2 CKD (47% of the patients) or Stage 3 CKD (53% of the
patients). This would be very unusual, even allowing for the me-
dian age of 65 years and the presence of cardiovascular disease
and hyperuricaemia. Indeed, a careful review of the manuscript,
the supplementary data and the trial protocol did not disclose
what additional criterion, on top of a normal or near normal
GFR, was used to diagnose CKD. In a later report, the authors in-
dicate that albuminuria was indeed not assessed [11]. It is likely
that the authors (together with reviewers and editors) missed
the clinical implications of the concept of CKD and used the
term Stage 1 or 2 CKD to indicate that the estimated creatinine
clearance (since they used the Cockcroft and Gault formula,
which, in fact, estimates creatinine clearance, not GFR) is
90 mL/min or between 60 and 89 mL/min, even if the patient
does not fulfill diagnostic criteria for CKD. In our opinion, this is
a dangerous use of the term CKD. Given the prestige of NEJM,
readers may imitate the journal and diagnose CKD in individu-
als with normal renal function and in the absence of any other
criteria to diagnose CKD. This may have negative consequences
for the individual from the point of view of a wrong diagnosis
and potential insurance issues, among others. Furthermore,
this may have negative consequences for the medical commu-
nity at large by creating confusion about the CKD concept and
assuming that 100% of the population has CKD or, conversely,
that a diagnosis of CKD G1A1 does not in fact reflect the real ex-
istence of CKD, thus depriving the term of its meaning and con-
sequences when applied to someone that does have CKD G1A1
(e.g. an individual with autosomal dominant polycystic kidney
disease and normal GFR and albuminuria values).
CONCLUSIONS
The medical community should be especially careful with lan-
guage and make an effort to use appropriately terms implying
specific diseases or that have implications for health. CKD is a
case in point, confusion being generated by using the terms
CKD Stage 1 or 2 or CKD categories G1A1 or G2A1 to refer to indi-
viduals who do not have CKD or have no evidence of CKD.
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FIGURE 2: Data presented in Table 1 of the recent 2018 NEJM manuscript by
White et al. [5]. All 6190 participants were reported to have CKD. Patients were
randomized to either febuxostat (N¼ 3098) or allopurinol (N¼3092). The table
legend stated that ‘estimated creatinine clearance was calculated with the use
of the Cockcroft–Gault formula and was corrected for ideal body weight. A value
of 60 mL per minute or more indicated Stage 1 or 2 chronic kidney disease, and a
value of at least 30 but less than 60 mL per minute indicated Stage 3 chronic kid-
ney disease’. However, no other evidence of CKD (e.g. such as pathological albu-
minuria in those with creatinine clearance >60 mL/min) was provided. Indeed,
albuminuria data were not available [11].
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